Genovis AB (publ.) (GENO.ST) stock: key figures, P/E, revenue and dividend
Health Care · Biotechnology · Sweden · ISIN SE0002485979
Genovis AB (publ.) financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 130.36 m SEK | 128.95 m SEK |
| Gross profit | 114.97 m SEK | 27.49 m SEK |
| Operating income | 45.73 m SEK | 27.49 m SEK |
| EBIT | 45.73 m SEK | 27.49 m SEK |
| Net income | 32.92 m SEK | 23.50 m SEK |
| Diluted EPS – continuing operations | 0.50 SEK | 0.36 SEK |
Full history since 2008, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Genovis AB (publ.)
Genovis AB (publ.) develops and sells tools for the development of new treatment methods and diagnostics in North America, Europe, and Asia. The company provides FabRICATOR, FabALACTICA, FabRICATOR Z, GingisKHAN, FabULOUS (SpeB), a cysteine protease; FabDELLO, a protease that digests human IgG1; IgASAP, an IgA-digesting enzyme; and IgMBRAZOR, an IgM-specific protease. It also offers GlySERIAS, an enzyme that digests flexible glycine-rich fusion protein linkers; GlyCLICK, a conjugation technology; TransGLYCIT, a platform technology; and GingisREX, a protease that digests proteins C-terminally of arginine residues. In addition, the company offers OmniGLYZOR, a mixture of immobilized enzymes; PNGase F, a glycoamidase; OpeRATOR, an O-glycan-specific protease; ImpaRATOR, an O-glycan-dependent protease; OglyZOR, an endoglycosidase; SialEXO, a sialidase product; FucosEXO, a mix of a-Fucosidases; GalactEXO, a ß-Galactosidase mix; GalNAcEXO, an a-N-Acetylgalactosaminidase; and GlycOCATCH, an affinity resin. Further, it provides GlycINATOR (EndoS2), an IgG-specific endoglycosidase; IgGZERO (EndoS), an IgG-specific endoglycosidase; Anti-FabRICATOR (Anti-IdeS), a family of antibody products; and Anti-FabRICATOR Z (Anti-IdeZ), a goat polyclonal antibody, as well as SEQURNA RNase Inhibitor Thermostable. Additionally, the company offers antibodies, proteins, antigens, kits, and cell culture products; bioprocess and gene therapy services; and services, such as SmartEnzymes fragmentation and conjugation, antibody LC-MS analysis, and customized antibody services. It serves biotech and pharmaceutical, contract research, and contract manufacturing companies. The company was founded in 1999 and is headquartered in Kävlinge, Sweden.
More stocks
- Gevelot (ALGEV.PA)
- Iron Force Industrial Co Ltd (2228.TW)
- Neostellar Capital Corp. (NSLR)
- Saniona AB (SANION.ST)
- United Fiber Optic Communication Inc. (4903.TWO)
- SUTRO BIOPHARMA, INC. (STRO)
- Huckleberry.ai, Inc. (HUCK)
- Interlife General Insurance S.A. (INLIF.AT)
- LEE ENTERPRISES, Inc (LEE)
- Kolon Globalco (003070.KS)
- Sammok S-Form Co.Ltd (018310.KQ)
- i-Scream Media CO., LTD. (461300.KQ)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.